Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.
复制标题
DOI：
10.1002/cac2.12197
复制
发表时间：
2021-10
期刊：
影响因子：
--
通讯作者：
Xu R
中科院分区：
文献类型：
--
作者：
Qiu H;Cao S;Xu R
在中国，癌症是导致死亡的主要原因之一，也是一个主要的经济负担。研究中国与发达国家在癌症类型和控制策略上的差异，可以为政策规划提供参考，有助于改善癌症控制措施。在这项研究中，我们回顾了中国癌症发病率和死亡率以及残疾调整生命年（DALY）负担的比率和趋势，并将其与美国（US）和英国（UK）进行了比较。中国、美国和英国的癌症发病率、死亡率和DALY数据来自GLOBOCAN 2020在线数据库、全球疾病负担（GBD） 2019研究和五大洲癌症发病率数据库（CI5 plus）。采用关节点回归模型分析了中国、美国和英国癌症发病率和死亡率的趋势，计算了年变化百分比（APCs），并确定了最佳拟合关节点。据估计，2020年中国新诊断的癌症病例为4568754例，癌症死亡人数为3002899人。此外，癌症在中国导致67,340,309例DALYs。与美国和英国相比，中国的癌症发病率较低，但癌症死亡率和DALY率较高。此外，中国的癌症谱正在发生变化，肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担迅速增加，肝癌、胃癌、食管癌和宫颈癌的发病率高，负担重。中国的癌症谱正在从一个发展中国家转变为一个发达国家。人口老龄化和不健康生活方式的增加将继续增加中国的癌症负担。因此，中国有关部门应参照发达国家已确立的癌症控制实践，同时考虑到中国不同地区癌症类型的多样性，调整国家癌症控制规划。中国的癌症谱正在发生变化，“富人癌”（肺癌、乳腺癌、结直肠癌和前列腺癌）的发病率和负担迅速增加，而“穷人癌”（肝癌、胃癌、食道癌和宫颈癌）的发病率高，负担重。
Cancer is one of the leading causes of death and a main economic burden in China. Investigating the differences in cancer patterns and control strategies between China and developed countries could provide reference for policy planning and contribute to improving cancer control measures. In this study, we reviewed the rates and trends of cancer incidence and mortality and disability‐adjusted life year (DALY) burden in China, and compared them with those in the United States (US) and the United Kingdom (UK). Cancer incidence, mortality, and DALY data for China, US and UK were obtained from the GLOBOCAN 2020 online database, Global Burden of Disease (GBD) 2019 study, and Cancer Incidence in Five Continents plus database (CI5 plus). Trends of cancer incidence and mortality in China, US, and UK were analyzed using Joinpoint regression models to calculate annual percent changes (APCs) and identify the best‐fitting joinpoints. An estimated 4,568,754 newly diagnosed cancer cases and 3,002,899 cancer deaths occurred in China in 2020. Additionally, cancers resulted in 67,340,309 DALYs in China. Compared to the US and UK, China had lower cancer incidence but higher cancer mortality and DALY rates. Furthermore, the cancer spectrum of China was changing, with a rapid increase incidence and burden of lung, breast, colorectal, and prostate cancer in addition to a high incidence and heavy burden of liver, stomach, esophageal, and cervical cancer. The cancer spectrum of China is changing from a developing country to a developed country. Population aging and increase of unhealthy lifestyles would continue to increase the cancer burden of China. Therefore, the Chinese authorities should adjust the national cancer control program with reference to the practices of cancer control which have been well‐established in the developed countries, and taking consideration of the diversity of cancer types by of different regions in China at the same time. The cancer spectrum of China is changing, with a rapidly increase incidence and burden of "cancers of the rich" (lung, breast, colorectal, and prostate cancer) in addition to a high incidence and heavy burden of “cancers of the poor” (liver, stomach, esophageal, and cervical cancer).
登录
查看更多内容
影响因子：
51.1
作者：
de Sanjose, Silvia;Quint, Wim G. V.;Xavier Bosch, F.
通讯作者：
Xavier Bosch, F.
影响因子：
16.2
作者：
Feng, Rui-Mei;Zong, Yi-Nan;Xu, Rui-Hua
通讯作者：
Xu, Rui-Hua
影响因子：
5.5
作者：
Hall, Ingrid J.;Tangka, Florence K. L.;Breen, Nancy
通讯作者：
Breen, Nancy
影响因子：
34.3
作者：
Arbyn, Marc;Weiderpass, Elisabete;Bray, Freddie
通讯作者：
Bray, Freddie
DOI：
10.1016/s0140-6736(17)33326-3
发表时间：
2018-03-17
期刊：
Lancet (London, England)
影响因子：
--
作者：
Allemani C;Matsuda T;Di Carlo V;Harewood R;Matz M;Nikšić M;Bonaventure A;Valkov M;Johnson CJ;Estève J;Ogunbiyi OJ;Azevedo E Silva G;Chen WQ;Eser S;Engholm G;Stiller CA;Monnereau A;Woods RR;Visser O;Lim GH;Aitken J;Weir HK;Coleman MP;CONCORD Working Group
通讯作者：
CONCORD Working Group